Treatment of hepatitis C virus infection with human ezrin peptide one (HEP1) in HIV infected patients.

Salamov G, Holms R, Bessler WG, Ataullakhanov R

Arzneimittel-Forschung1 Jan 2007Cited by 4 (Europe PMC)

PMID17803064DOI10.1055/s-0031-1296637PepBankPUB-17803064

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study17

17 results from studies that gave the peptide. 17 results from people.

01HumanNon-randomized trialEfficacy outcome
In the pooled HCV/HIV cohort, 10 of 37 patients had viral-load reductions between -7 log and -3 log after HEP1.
In plain wordsIn the combined studies, 10 of 37 patients had HCV reductions between -7 log and -3 log after HEP1.
Peptide
Gepon
Outcome
DecreasePooled viral-load reduction between minus seven and minus three log
Study
n = 37
Outcome group
Antiviral activity · Infection
Studied dose
Dose not stated · oralAs given in this study (human).
Measurements
Patients
10 patients
Reduction between -7 log and -3 log
Patients
27%
Reduction between -7 log and -3 log
Source sentences
Summary
in 37 HCV+HIV patients, HEP1 therapy gave the following results: 10 of 37 (27%) HCV+HIV patients showed a reduction of viral load between -7 log (-10,000,000x) and -3 log (-1000x)
1 context sentence(design, population, supporting numbers)
Summary · context
This report shows the therapeutic benefit of HEP1 (human ezrin peptide 324-337; TEKKRRETVEREKE) monotherapy of hepatitis C virus (HCV) infection in HIV infected patients in two clinical studies.
Report a problemFND-1780306409
02HumanNon-randomized trialEfficacy outcome
In the pooled HCV/HIV cohort, 4 of 37 patients had a -3 log viral-load reduction after HEP1.
In plain wordsIn the combined studies, 4 of 37 patients had a -3 log HCV reduction after HEP1.
Peptide
Gepon
Outcome
DecreasePooled viral-load reduction of minus three log
Study
n = 37
Outcome group
Antiviral activity · Infection
Studied dose
Dose not stated · oralAs given in this study (human).
Measurements
Patients
4 patients
Reduction of -3 log
Patients
11%
Reduction of -3 log
Source sentences
Summary
4 of 37 (11%) a reduction of -3 log (-1000x)
1 context sentence(design, population, supporting numbers)
Summary · context
This report shows the therapeutic benefit of HEP1 (human ezrin peptide 324-337; TEKKRRETVEREKE) monotherapy of hepatitis C virus (HCV) infection in HIV infected patients in two clinical studies.
Report a problemFND-1780306410
03HumanNon-randomized trialEfficacy outcome
In the pooled HCV/HIV cohort, 6 of 37 patients had a -2 log viral-load reduction after HEP1.
In plain wordsIn the combined studies, 6 of 37 patients had a -2 log HCV reduction after HEP1.
Peptide
Gepon
Outcome
DecreasePooled viral-load reduction of minus two log
Study
n = 37
Outcome group
Antiviral activity · Infection
Studied dose
Dose not stated · oralAs given in this study (human).
Measurements
Patients
6 patients
Reduction of -2 log
Patients
16%
Reduction of -2 log
Source sentences
Summary
6 of 37 (16%) a reduction of -2 log (-100x)
1 context sentence(design, population, supporting numbers)
Summary · context
This report shows the therapeutic benefit of HEP1 (human ezrin peptide 324-337; TEKKRRETVEREKE) monotherapy of hepatitis C virus (HCV) infection in HIV infected patients in two clinical studies.
Report a problemFND-1780306411
04HumanNon-randomized trialEfficacy outcome
In the pooled HCV/HIV cohort, 11 of 37 patients had a -1 log viral-load reduction after HEP1.
In plain wordsIn the combined studies, 11 of 37 patients had a -1 log HCV reduction after HEP1.
Peptide
Gepon
Outcome
DecreasePooled viral-load reduction of minus one log
Study
n = 37
Outcome group
Antiviral activity · Infection
Studied dose
Dose not stated · oralAs given in this study (human).
Measurements
Patients
11 patients
Reduction of -1 log
Patients
30%
Reduction of -1 log
Source sentences
Summary
11 of 37 (30%) a reduction of -1 log (-10x)
1 context sentence(design, population, supporting numbers)
Summary · context
This report shows the therapeutic benefit of HEP1 (human ezrin peptide 324-337; TEKKRRETVEREKE) monotherapy of hepatitis C virus (HCV) infection in HIV infected patients in two clinical studies.
Report a problemFND-1780306412
05HumanNon-randomized trialEfficacy outcome
In the pooled HCV/HIV cohort, 6 of 37 patients had a reported reduction of less than -1 log after HEP1.
In plain wordsIn the combined studies, 6 of 37 patients had a reported HCV reduction of less than -1 log after HEP1.
Peptide
Gepon
Outcome
DecreasePooled viral-load reduction less than minus one log
Study
n = 37
Outcome group
Antiviral activity · Infection
Studied dose
Dose not stated · oralAs given in this study (human).
Measurements
Patients
6 patients
Reduction of less than -1 log
Patients
16%
Reduction of less than -1 log
Source sentences
Summary
6 of 37 (16%) a reduction of less than -1 log (-10x)
1 context sentence(design, population, supporting numbers)
Summary · context
This report shows the therapeutic benefit of HEP1 (human ezrin peptide 324-337; TEKKRRETVEREKE) monotherapy of hepatitis C virus (HCV) infection in HIV infected patients in two clinical studies.
Report a problemFND-1780306413
06HumanNon-randomized trialEfficacy outcome
In the pooled HCV/HIV cohort, 0 of 37 patients had increased viral load after HEP1.
In plain wordsIn the combined studies, no patients had increased HCV levels after HEP1.
Peptide
Gepon
Outcome
Not applicablePooled patients with increased HCV viral load
Study
n = 37
Outcome group
Antiviral activity · Infection
Studied dose
Dose not stated · oralAs given in this study (human).
Measurements
Patients with increased viral load
0 patients
Pooled HEP1 cohort
Patients with increased viral load
0%
Pooled HEP1 cohort
Source sentences
Summary
0 of 37 (0%) had an increase in viral load
1 context sentence(design, population, supporting numbers)
Summary · context
This report shows the therapeutic benefit of HEP1 (human ezrin peptide 324-337; TEKKRRETVEREKE) monotherapy of hepatitis C virus (HCV) infection in HIV infected patients in two clinical studies.
Report a problemFND-1780306414
07HumanNon-randomized trialEfficacy outcome
In the pooled HCV/HIV cohort, the average viral-load reduction after HEP1 was -2 log (-100x).
In plain wordsIn the combined studies, the average HCV reduction after HEP1 was -2 log (-100x).
Peptide
Gepon
Outcome
DecreasePooled average HCV viral-load reduction
Study
n = 37
Outcome group
Antiviral activity · Infection
Studied dose
Dose not stated · oralAs given in this study (human).
Measurements
Average viral-load reduction
−2 log
All 37 patients
Source sentences
Summary
the average reduction in viral load for all 37 patients was -2 log (-100x).
1 context sentence(design, population, supporting numbers)
Summary · context
This report shows the therapeutic benefit of HEP1 (human ezrin peptide 324-337; TEKKRRETVEREKE) monotherapy of hepatitis C virus (HCV) infection in HIV infected patients in two clinical studies.
Report a problemFND-1780306415
08HumanNon-randomized trialEfficacy outcome
In Pilot Study I, 16 of 18 HCV/HIV-coinfected patients responded to HEP1 with significant HCV viral-load reductions.
In plain wordsIn the first study, 16 of 18 patients with HCV and HIV had significant reductions in HCV levels after HEP1.
Peptide
Gepon
Outcome
DecreasePilot Study I HCV viral-load response
Study
n = 18
Outcome group
Antiviral activity · Infection
Studied dose
Dose not stated · oralAs given in this study (human).
Measurements
Patients with response
16 patients
Pilot Study I
Source sentences
Summary
In the Pilot Study I, 16 of 18 patients responded well to the treatment with significant reductions of HCV viral load and a normalization of serum liver enzymes.
1 context sentence(design, population, supporting numbers)
Summary · context
This report shows the therapeutic benefit of HEP1 (human ezrin peptide 324-337; TEKKRRETVEREKE) monotherapy of hepatitis C virus (HCV) infection in HIV infected patients in two clinical studies.
Report a problemFND-1780306401
09HumanNon-randomized trialEfficacy outcome
In Pilot Study I, the response in 16 of 18 HCV/HIV-coinfected patients included serum liver-enzyme normalization after HEP1.
In plain wordsIn the first study, the response in 16 of 18 patients included normalization of liver enzymes after HEP1.
Peptide
Gepon
Outcome
Not applicablePilot Study I serum liver-enzyme normalization
Study
n = 18
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated · oralAs given in this study (human).
Measurements
Patients with response
16 patients
Pilot Study I
Source sentences
Summary
In the Pilot Study I, 16 of 18 patients responded well to the treatment with significant reductions of HCV viral load and a normalization of serum liver enzymes.
1 context sentence(design, population, supporting numbers)
Summary · context
This report shows the therapeutic benefit of HEP1 (human ezrin peptide 324-337; TEKKRRETVEREKE) monotherapy of hepatitis C virus (HCV) infection in HIV infected patients in two clinical studies.
Report a problemFND-1780306402
10HumanNon-randomized trialEfficacy outcome
In Pilot Study I, HCV RNA became undetectable in 8 of 18 patients after HEP1.
In plain wordsIn the first study, HCV became undetectable in 8 of 18 patients after HEP1.
Peptide
Gepon
Outcome
DecreasePilot Study I undetectable HCV RNA
Study
n = 18
Outcome group
Antiviral activity · Infection
Studied dose
Dose not stated · oralAs given in this study (human).
Measurements
Patients with undetectable HCV RNA
8 patients
Pilot Study I
Source sentences
Summary
In 8 of 18 patients, HCV RNA became undetectable, and 3 of 8 interferon/ribavirin treatment failure patients showed undetectable HCV load following HEP1 treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
This report shows the therapeutic benefit of HEP1 (human ezrin peptide 324-337; TEKKRRETVEREKE) monotherapy of hepatitis C virus (HCV) infection in HIV infected patients in two clinical studies.
Report a problemFND-1780306403
11HumanNon-randomized trialEfficacy outcome
HCV load was undetectable in 3 of 15 patients 30 days after a 30-day HEP1 course ended.
In plain wordsHCV was undetectable in 3 of 15 patients 30 days after a 30-day HEP1 course ended.
Peptide
Gepon
Outcome
DecreaseUndetectable viral load after treatment completion
Study
n = 15
Outcome group
Antiviral activity · Infection
Studied dose
Dose not stated · oral · 30 daysAs given in this study (human).
Measurements
Patients with undetectable viral load
3 patients
After HEP1 treatment
Patients with undetectable viral load
20%
After HEP1 treatment
Source sentences
Summary
Three of 15 patients (20%) showed an undetectable viral load 30 days after the end of a 30-day course of HEP1 treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
This report shows the therapeutic benefit of HEP1 (human ezrin peptide 324-337; TEKKRRETVEREKE) monotherapy of hepatitis C virus (HCV) infection in HIV infected patients in two clinical studies.
Report a problemFND-1780306407
12HumanNon-randomized trialEfficacy outcome
In the second study, 8 of 10 HCV/HIV-coinfected patients responded to HEP1 with pronounced HCV viral-load reductions.
In plain wordsIn the second study, 8 of 10 patients had pronounced reductions in HCV levels after HEP1.
Peptide
Gepon
Outcome
DecreaseSecond-study HCV viral-load response
Study
n = 10
Outcome group
Antiviral activity · Infection
Studied dose
Dose not stated · oralAs given in this study (human).
Measurements
Patients with response
8 patients
Second study
Source sentences
Summary
In the second study, 8 of 10 patients responded well to the treatment with a pronounced reduction of the HCV viral load and a normalization of serum liver enzymes.
1 context sentence(design, population, supporting numbers)
Summary · context
This report shows the therapeutic benefit of HEP1 (human ezrin peptide 324-337; TEKKRRETVEREKE) monotherapy of hepatitis C virus (HCV) infection in HIV infected patients in two clinical studies.
Report a problemFND-1780306405
13HumanNon-randomized trialEfficacy outcome
In the second study, the response in 8 of 10 HCV/HIV-coinfected patients included serum liver-enzyme normalization after HEP1.
In plain wordsIn the second study, the response in 8 of 10 patients included normalization of liver enzymes after HEP1.
Peptide
Gepon
Outcome
Not applicableSecond-study serum liver-enzyme normalization
Study
n = 10
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated · oralAs given in this study (human).
Measurements
Patients with response
8 patients
Second study
Source sentences
Summary
In the second study, 8 of 10 patients responded well to the treatment with a pronounced reduction of the HCV viral load and a normalization of serum liver enzymes.
1 context sentence(design, population, supporting numbers)
Summary · context
This report shows the therapeutic benefit of HEP1 (human ezrin peptide 324-337; TEKKRRETVEREKE) monotherapy of hepatitis C virus (HCV) infection in HIV infected patients in two clinical studies.
Report a problemFND-1780306406
14HumanNon-randomized trialEfficacy outcome
After HEP1 treatment, HCV load was undetectable in 3 of 8 patients with prior interferon/ribavirin treatment failure.
In plain wordsAfter HEP1, HCV became undetectable in 3 of 8 patients whose previous interferon/ribavirin treatment failed.
Peptide
Gepon
Outcome
DecreaseUndetectable HCV after interferon/ribavirin failure
Study
n = 8
Outcome group
Antiviral activity · Infection
Studied dose
Dose not stated · oralAs given in this study (human).
Measurements
Patients with undetectable HCV load
3 patients
Prior interferon/ribavirin treatment failure
Source sentences
Summary
In 8 of 18 patients, HCV RNA became undetectable, and 3 of 8 interferon/ribavirin treatment failure patients showed undetectable HCV load following HEP1 treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
This report shows the therapeutic benefit of HEP1 (human ezrin peptide 324-337; TEKKRRETVEREKE) monotherapy of hepatitis C virus (HCV) infection in HIV infected patients in two clinical studies.
Report a problemFND-1780306404
15HumanNon-randomized trialEfficacy outcome
In both HCV/HIV studies, all HCV genotypes were sensitive to HEP1 treatment.
In plain wordsIn both studies of patients with HCV and HIV, all HCV genotypes were sensitive to HEP1.
Peptide
Gepon
Outcome
Not applicableHCV genotype sensitivity
Study
n: not reported in source
Outcome group
Antiviral activity · Infection
Studied dose
Dose not stated · oralAs given in this study (human).
Source sentences
Summary
In both studies, all genotypes of HCV were sensitive to HEP1 treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
This report shows the therapeutic benefit of HEP1 (human ezrin peptide 324-337; TEKKRRETVEREKE) monotherapy of hepatitis C virus (HCV) infection in HIV infected patients in two clinical studies.
Report a problemFND-1780306408
16HumanNon-randomized trialSafety outcome
In the HCV/HIV studies, no adverse reactions or side effects were detected during HEP1 therapy.
In plain wordsIn patients with HCV and HIV, no adverse reactions or side effects were detected with HEP1.
Peptide
Gepon
Outcome
Not applicableAdverse reactions and side effects
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated · oralAs given in this study (human).
Source sentences
Summary
No adverse reactions or side effects were detected and the improving CD4/CD8 ratio showed that the therapy had no negative impact on the immunological status.
1 context sentence(design, population, supporting numbers)
Summary · context
This report shows the therapeutic benefit of HEP1 (human ezrin peptide 324-337; TEKKRRETVEREKE) monotherapy of hepatitis C virus (HCV) infection in HIV infected patients in two clinical studies.
Report a problemFND-1780306416
17HumanNon-randomized trialMechanism
In the HCV/HIV studies, the CD4/CD8 ratio improved with HEP1 therapy.
In plain wordsIn patients with HCV and HIV, the CD4/CD8 ratio improved with HEP1.
Peptide
Gepon
Outcome
Not applicableCD4/CD8 ratio
Study
n: not reported in source
Outcome group
Immune response · Immune and inflammation
Studied dose
Dose not stated · oralAs given in this study (human).
Source sentences
Summary
No adverse reactions or side effects were detected and the improving CD4/CD8 ratio showed that the therapy had no negative impact on the immunological status.
1 context sentence(design, population, supporting numbers)
Summary · context
This report shows the therapeutic benefit of HEP1 (human ezrin peptide 324-337; TEKKRRETVEREKE) monotherapy of hepatitis C virus (HCV) infection in HIV infected patients in two clinical studies.
Report a problemFND-1780306417

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
27 Oct 2026, 18:20 UTC
Study results updated
Version 1
27 Oct 2026, 16:32 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.